Glance Pay Announces Its Technology Has Eliminated Fraud Over an 8 Month Period
Sep 07, 2017 12:01 pm UTC| Business
VANCOUVER, British Columbia, Sept. 07, 2017 -- Glance Technologies Inc. (OTCQB:GLNNF), (CSE:GET.CN), (CSE:GET.WT), (FKT:GJT) is proud to announce another milestone for its fraud prevention technology: since Glance...
ABcann Global Appoints Barry Fishman as Chief Executive Officer
Sep 07, 2017 12:01 pm UTC| Business
NAPANEE, Ontario, Sept. 07, 2017 -- ABcann Global Corporation (TSX-V:ABCN) ("ABcann" or the "Company") is pleased to announce the appointment of Barry Fishman as Chief Executive Officer of the Company, effective October...
NETSOL Technologies Appoints Former Toyota Leasing Executive Henry Tolentino to its Advisory Board
Sep 07, 2017 12:01 pm UTC| Business
CALABASAS, Calif., Sept. 07, 2017 -- NETSOL Technologies, Inc. (NASDAQ:NTWK), a global business services and enterprise application solutions provider, has appointed former Toyota Leasing executive Henry Tolentino to...
SpotX Announces New Header Bidding Suite Designed Specifically for Video
Sep 07, 2017 12:01 pm UTC| Business
DENVER, Sept. 07, 2017 -- Video ad serving platform SpotX today announced a new header bidding suite built specifically for video, featuring a server-side wrapper and an advancement of the company's shift from tag-based...
Caladrius Biosciences to Participate at Upcoming September Conferences
Sep 07, 2017 12:01 pm UTC| Business
BASKING RIDGE, N.J., Sept. 07, 2017 -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and...
Flexera Promotes from within for Director of Australia and New Zealand
Sep 07, 2017 12:01 pm UTC| Business
ITASCA, Ill., Sept. 07, 2017 -- Flexera, the company that’s reimagining how software is bought, sold, managed and secured, announced today the appointment of Hugh Darvall as its new Director of Australia and New...
Sep 07, 2017 12:01 pm UTC| Business
AUSTIN, Texas, Sept. 07, 2017 -- XBiotech Inc. (NASDAQ:XBIT) announced today that results from the investigator sponsored randomized Phase 2 study evaluating XBiotech’s True Human™ antibody, MABp1, as a treatment for...